Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 12
2005 6
2006 9
2007 3
2008 2
2009 6
2010 6
2011 5
2012 3
2013 2
2017 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H, Ando M, Itabashi M, Nakajima G, Kawakami K, Hamano M, Hirai E, Yokomizo H, Okuyama R, Araida T, Yoshimatsu K, Kameoka S, Hayashi K. Kuramochi H, et al. Among authors: kawakami k. Cancer Chemother Pharmacol. 2017 Mar;79(3):579-585. doi: 10.1007/s00280-017-3255-3. Epub 2017 Feb 17. Cancer Chemother Pharmacol. 2017. PMID: 28213683 Clinical Trial.
Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J. Pyko IV, et al. Among authors: kawakami k. Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28. Carcinogenesis. 2013. PMID: 23715499 Free article.
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, Tanaka T, Takegami T, Tomosugi N, Minamoto T, Motoo Y. Shimasaki T, et al. Among authors: kawakami k. J Gastroenterol. 2012 Mar;47(3):321-33. doi: 10.1007/s00535-011-0484-9. Epub 2011 Nov 1. J Gastroenterol. 2012. PMID: 22041920
61 results